VT-1598 is an orally active and selective fungal inhibitor targeting CYP51. VT-1598 shows anti-fungal activity against Candida auris[2].In Vitro:VT-1598 (0.015-8?μg/mL; 24 h) demonstrates in vitro activity against C. auris.
VT-1598 (0.03125-0.125?μg/mL; 24 h) shows highly effects in inhibiting the in vitro growth of clinical Candida isolates[2].In Vivo:VT-1598 (oral gavage; 5, 15, and 50?mg/kg; once daily; 7 d) treatment shows a significant and dose-dependent survival advantage, and dose-dependent reductions in fungal burden.
VT-1598 (oral gavage; 3.2, 8, and 20?mg/kg; once daily; 4 d) is present to a great extent in the plasma and tongue after oral administration in Act1-deficient mice infected with C. albicans[2].